Joint Meeting of the Pediatric Advisory Committee and the Drug Safety and Risk Management Advisory Committee: Singulair and Neuropsychiatric Events

Title	Joint Meeting of the Pediatric Advisory Committee and the Drug Safety and Risk Management Advisory Committee: Singulair and Neuropsychiatric Events
Date	Friday, September 27, 2019
Link	View the Advisory Committee Meeting Materials here
Related Links	Neuropsychiatric Events following Montelukast Use: A Propensity Score Matched Analysis FDA Safety Communication: FDA requires Boxed Warning for montelukast (Singulair)
Medical Product	Singulair montelukast
Health Outcome	inpatient depressive disorder outpatient depressive disorder self-harm suicide

Search form